Emami Limited (NSE: EMAMILTD | BSE: 531162)

By Raveendran R | Updated on:

Source: Emami Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners

Emami Limited operates as one of India’s prominent fast-moving consumer goods entities, focusing on personal care and healthcare categories anchored in traditional Ayurveda and backed by contemporary scientific research. The company’s operating engine bridges generational home remedies and everyday therapeutic care, creating high-margin, differentiated niche offerings rather than competing exclusively in commoditised mass FMCG segments.

CORE BUSINESS SEGMENTS & OPERATING HIGHLIGHTS:
  • Core Business & Market Position: Emami Limited is an Indian fast-moving consumer goods (FMCG) enterprise operating in personal care and healthcare solutions rooted in Ayurvedic formulations and natural ingredients. The company maintains leadership across niche consumer categories in India, including cooling oils (Navratna), antiseptic creams (BoroPlus), pain balms (Zandu Balm and Mentho Plus), and medicated hair oils (Kesh King).
  • FY26 Financial Trajectory: Consolidated Revenue from Operations stood at ₹3,779.51 Crores in FY 2025-26 compared to ₹3,809.19 Crores in FY 2024-25, navigating an unseasonal weak summer, transitional trade disruption from the GST 2.0 rate rationalisation, and geopolitical tensions in West Asia. Operating EBITDA was ₹963.64 Crores with an EBITDA margin of 25.50%, and Consolidated Profit After Tax (attributable to owners) reached ₹775.26 Crores.
  • Key Growth Catalyst: Rapid scaling of organised and digital channels, where e-commerce grew by 16% (led by a 2.2x expansion in quick commerce) to account for 14% of domestic revenues, while organised trade overall reached 32% of domestic business. Strategic additions in digital-first beauty and functional beverages, including majority control of IncNut Digital (Vedix, SkinKraft) and full ownership of Axiom Ayurveda (AloFrut), expanded addressable market depth.
  • Primary Balance Sheet / Operational Watchpoint: Emami maintains a strong net debt-free balance sheet with ₹2,923.98 Crores in net worth and ₹471.88 Crores in liquid investments, supporting healthy free cash flow generation. Working capital days moderated to 56 days, though inventory rose to ₹399.57 Crores (39 days) due to strategic pre-procurement against raw material cost volatility.
Metrics for FY 2025-26 Ended Mar 31, 2026
PROFIT & LOSS METRICS (₹ CR)
Revenue
₹3,779.51 Cr (▼ 0.8%)
Prev Year: ₹3,809.19 Cr
Gross Profit
₹2,641.50 Cr (▲ 1.0%)
Prev Year: ₹2,614.96 Cr
Operating Profit
₹772.08 Cr (▼ 7.5%)
Prev Year: ₹834.42 Cr
Net Profit
₹775.26 Cr (▼ 3.4%)
Prev Year: ₹802.74 Cr
Gross Margin
69.89 % (▲ 124 bps)
Prev Year: 68.65 %
Operating Margin
20.43 % (▼ 148 bps)
Prev Year: 21.91 %
PAT Margin
20.51 % (▼ 56 bps)
Prev Year: 21.07 %
Asset Turnover
0.99x (▼ 0.09 pts)
Prev Year: 1.08x
RETURN & CAPITAL EFFICIENCY METRICS
ROE
26.53 % (▼ 328 bps)
Prev Year: 29.80 %
ROCE
25.75 % (▼ 454 bps)
Prev Year: 30.30 %
ROA
20.21 % (▼ 251 bps)
Prev Year: 22.72 %
Cash ROE
27.39 % (▼ 587 bps)
Prev Year: 33.26 %
Cash ROCE
26.70 % (▼ 583 bps)
Prev Year: 32.53 %
BALANCE SHEET METRICS (₹ CR)
Total Assets
₹3,836.44 Cr (▲ 8.6%)
Prev Year: ₹3,533.62 Cr
Current Assets
₹1,934.86 Cr (▲ 11.6%)
Prev Year: ₹1,733.66 Cr
Total Liabilities
₹914.01 Cr (▲ 8.8%)
Prev Year: ₹840.27 Cr
Current Liabilities
₹838.25 Cr (▲ 7.6%)
Prev Year: ₹779.35 Cr
Total Equity
₹2,922.43 Cr (▲ 8.5%)
Prev Year: ₹2,693.36 Cr
Working Capital
₹1,096.61 Cr (▲ 14.9%)
Prev Year: ₹954.31 Cr
Current Ratio
2.31x (▲ 0.08 pts)
Prev Year: 2.22x
Total Debt
₹122.38 Cr (▲ 97.1%)
Prev Year: ₹62.08 Cr
Debt to Equity
0.04x (▲ 0.02 pts)
Prev Year: 0.02x
Debt to Assets
0.03x (▲ 0.01 pts)
Prev Year: 0.02x
Equity Multiplier
1.31x (- 0.00 pts)
Prev Year: 1.31x
CASH FLOW METRICS (₹ CR)
Operating Cash Flow
₹800.53 Cr (▼ 10.6%)
Prev Year: ₹895.86 Cr
CapEx
₹43.32 Cr (▼ 2.8%)
Prev Year: ₹44.57 Cr
Free Cash Flow
₹757.21 Cr (▼ 11.1%)
Prev Year: ₹851.29 Cr
FCF Margin
20.03 % (▼ 231 bps)
Prev Year: 22.35 %
CF to Debt
6.54x (▼ 7.89 pts)
Prev Year: 14.43x
ROCE (5Y Avg)
32.36 %
FY22–FY26 (5Y Avg)
ROE (5Y Avg)
30.82 %
FY22–FY26 (5Y Avg)
ROA (5Y Avg)
22.60 %
FY22–FY26 (5Y Avg)

📋 Quick Facts / Company Snapshot: Emami Limited (NSE: EMAMILTD | BSE: 531162)

  • Core Business & Market Position: Emami Limited is an Indian fast-moving consumer goods (FMCG) enterprise operating in personal care and healthcare solutions rooted in Ayurvedic formulations and natural ingredients. The company maintains leadership across niche consumer categories in India, including cooling oils (Navratna), antiseptic creams (BoroPlus), pain balms (Zandu Balm and Mentho Plus), and medicated hair oils (Kesh King).
  • FY26 Financial Trajectory: Consolidated Revenue from Operations stood at ₹3,779.51 Crores in FY 2025-26 compared to ₹3,809.19 Crores in FY 2024-25, navigating an unseasonal weak summer, transitional trade disruption from the GST 2.0 rate rationalisation, and geopolitical tensions in West Asia. Operating EBITDA was ₹963.64 Crores with an EBITDA margin of 25.50%, and Consolidated Profit After Tax (attributable to owners) reached ₹775.26 Crores.
  • Key Growth Catalyst: Rapid scaling of organised and digital channels, where e-commerce grew by 16% (led by a 2.2x expansion in quick commerce) to account for 14% of domestic revenues, while organised trade overall reached 32% of domestic business. Strategic additions in digital-first beauty and functional beverages, including majority control of IncNut Digital (Vedix, SkinKraft) and full ownership of Axiom Ayurveda (AloFrut), expanded addressable market depth.
  • Primary Balance Sheet / Operational Watchpoint: Emami maintains a strong net debt-free balance sheet with ₹2,923.98 Crores in net worth and ₹471.88 Crores in liquid investments, supporting healthy free cash flow generation. Working capital days moderated to 56 days, though inventory rose to ₹399.57 Crores (39 days) due to strategic pre-procurement against raw material cost volatility.
Attribute Disclosed Detail
Official Company Name Emami Limited
Corporate Identity Number (CIN) L63993WB1983PLC036030
Stock Exchange Listing NSE: EMAMILTD | BSE: 531162
Date of Incorporation / Founding Year Incorporated in 1983 (Foundational business established in 1974)
Founders / Key Founding Figures Shri R. S. Agarwal and Shri R. S. Goenka
Registered Office & Corporate Headquarters Emami Tower, 687, Anandapur, E.M. Bypass, Kolkata – 700107, West Bengal, India
Telephone & Official Investor Relations Email Phone: +91 33 66136264 | Email: investors@emamigroup.com
Chairman Emeritus & Non-Executive Director Shri R. S. Agarwal (DIN: 00152996)
Chairman & Non-Executive Director Shri R. S. Goenka (DIN: 00152880)
Vice-Chairman & Managing Director Shri Harsha V. Agarwal (DIN: 00150089)
Vice-Chairman & Whole Time Director Shri Mohan Goenka (DIN: 00150034)
CEO – Finance, Strategy & Business Development and CFO Shri N. H. Bhansali (FCA No: 055211)
Company Secretary & Compliance Officer Shri Ravi Varma (Membership No: FCS 9531)
Promoter & Holding Group Emami Group (Promoter and Promoter Group holding: 54.84%)
Industry / Sector Classification Fast Moving Consumer Goods (FMCG) / Ayurvedic and Personal Care (NIC Code 21003 & 20237)
Total Employees / Permanent & Contractual Split Total Workforce: 5,447 (Employees: 2,090 Permanent, 69 Non-Permanent; Workers: 1,007 Permanent, 2,281 Non-Permanent)
Employee Retention Rate 88%
Manufacturing Plants / Operating Footprint 6 Captive Units (5 in India: Pacharia, Amingaon, Pantnagar, Masat, Vapi; 1 in Gazipur, Bangladesh) + 35 Third-Party Units
Credit Ratings & Rating Agency CARE Ratings: CARE AA+; Stable / CARE A1+ | India Ratings & Research: IND AA+/Stable / IND A1+
Statutory Auditors M/s. S. R. Batliboi & Co. LLP, Chartered Accountants (FRN: 301003E/E300005)
Secretarial Auditors M/s MKB & Associates, Practicing Company Secretaries (FRN: P2010WB042700)
Cost Auditors M/s. V. K. Jain & Co., Cost Accountants (FRN: 00049)
Registrar and Share Transfer Agent (RTA) Maheshwari Datamatics Private Limited, 23, R. N. Mukherjee Road, Kolkata – 700001, West Bengal

🏢 The Corporate Identity: Emami Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Emami Limited operates as one of India’s prominent fast-moving consumer goods entities, focusing on personal care and healthcare categories anchored in traditional Ayurveda and backed by contemporary scientific research. The company’s operating engine bridges generational home remedies and everyday therapeutic care, creating high-margin, differentiated niche offerings rather than competing exclusively in commoditised mass FMCG segments.

The business model relies on five core pillars: disciplined product formulation combining botanicals with validated bio-actives, scalable captive and third-party contract manufacturing, an expansive multichannel distribution architecture covering over 5.4 million retail outlets across India, high-impact brand building supported by celebrity ambassadors and regional storytelling, and targeted capital deployment into inorganic platforms. By expanding its non-seasonal portfolio to 56% of domestic revenues, Emami has structurally insulated its operational margins against cyclical climatic fluctuations.

The Founders, Promoters & Their Legacy

Emami was founded on the lifelong partnership and entrepreneurial vision of two childhood friends, Shri Radhe Shyam Agarwal and Shri Radhe Shyam Goenka. Commencing operations in Kolkata in the mid-1970s, the founders established an operating philosophy encapsulated by the corporate phrase “Kuch toh alag baat honi chahiye” (There must be something distinctive). This mantra steered the group away from me-too products toward high-value, problem-solving consumer categories.

The second-generation leadership, headed by Shri Harsha Vardhan Agarwal (Vice-Chairman & Managing Director) and Shri Mohan Goenka (Vice-Chairman & Whole Time Director), has steered the enterprise toward institutionalisation, digital transformation, and modern route-to-market execution. Executive Director Smt. Priti A. Sureka leads strategic brand positioning and corporate responsibility, while Whole Time Directors Shri Sushil Kumar Goenka and Shri Prashant Goenka oversee operational governance, manufacturing networks, and international market development.

The Journey: Corporate History & Key Milestones

Emami’s corporate trajectory is characterized by strategic brand acquisitions, organic product innovations, and continuous channel adaptation across half a century:

  • 1974: Founders Shri R. S. Agarwal and Shri R. S. Goenka commence cosmetics and Ayurvedic manufacturing in Kolkata, establishing the foundation of Emami.
  • 1978: Strategic acquisition of Himani Limited, providing established production infrastructure and legacy proprietary formulations.
  • 1982–1984: Launch of BoroPlus Antiseptic Cream, which expanded to become an iconic multi-purpose skincare franchise across North, East, and Central India.
  • 1989: Launch of Navratna Oil, pioneering the therapeutic “cool oil” category designed for physical relief, mental stress alleviation, and relaxation.
  • 2005: Initial Public Offering (IPO) of Emami Limited; commercial introduction of Fair and Handsome, creating India’s pioneer male grooming and fairness skincare segment.
  • 2008: Transformative acquisition of Zandu Pharmaceuticals Works Limited for ₹713 Crores, integrating historical Ayurvedic formulations such as Zandu Balm, Zandu Chyavanprash, and Zandu Pancharishta into the healthcare basket.
  • 2015: Acquisition of the Kesh King hair and scalp care business, establishing Emami’s commanding footprint in Ayurvedic medicinal hair oils and anti-hairfall shampoos.
  • 2019: Acquisition of Creme 21, an iconic German skincare brand with established distribution networks across the Middle East and Europe.
  • 2022: Acquisition of the Dermicool prickly heat and cooling powder brand, cementing Emami’s category leadership in summer personal care.
  • FY 2025-26: Relaunch of Kesh King Gold and rebranding of Fair and Handsome to Smart And Handsome; initial acquisition tranche executed for Axiom Ayurveda (AloFrut juices) and IncNut Digital (Vedix, SkinKraft).

The Corporate Umbrella & Group Structure

Emami Limited serves as the consumer-facing flagship of the broader Emami Group, an Indian multi-business conglomerate with independent operational interests in paper and packaging boards (Emami Paper Mills Limited), edible oils and food processing (Emami Agrotech Limited), real estate infrastructure (Emami Realty Limited), and retail pharmacy (Emami Frank Ross Limited). Emami Limited functions autonomously with independent governance oversight, maintaining strict arm’s-length commercial arrangements and zero cross-collateralisation of operating assets with promoter group businesses.

⚙️ The Business Engine: Emami Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

In accordance with Ind AS 108 Operating Segments, Emami Limited operates primarily in a single reportable operating segment: “Personal and Health Care”. The internal reporting structure evaluated by the Chief Operating Decision Maker (CODM) reviews operational performance holistically around consumer wellness, therapeutic healthcare, and beauty formulations.

Business Category / Format Revenue Contribution (%) Product Classes & Key Sub-categories Operational Dynamics & Focus Areas
Ayurvedic & Unani Preparations 85.00% Therapeutic oils, herbal balms, digestive tonics, Chyavanprash, medicinal hair oils High gross-margin profile; core domestic healthcare & pain management engine
Cosmetics & Toiletries 11.00% Antiseptic creams, body lotions, prickly heat talcs, face washes, male grooming Transitioning into multi-format personal care platforms and year-round hydration
Hair Oils, Shampoos & Dyes 2.00% Light hair oils, specialized serums, anti-dandruff solutions, herbal shampoos Targeted premiumisation, salon integration, and science-backed hair growth actives
Other Consumer Offerings 2.00% D2C personal care lines, functional wellness formats, trading goods Incubating digital-first brands, D2C subscriptions, and emerging retail concepts

The Product & Service Catalog

Emami manufactures, packages, and markets a broad portfolio exceeding 1,000 distinct SKUs spanning healthcare, personal care, beauty, and OTC wellness:

  • Healthcare & OTC Therapeutics: Zandu Balm, Zandu Balm Ultra Power, Mentho Plus Balm, Mentho Plus Total, Fast Relief Spray & Gel, Zandu Ortho Vedic Oil, Zandu Pancharishta, Zandu Nityam, Zandu Kesari Jivan, and Zandu Chyavanprash.
  • Cooling & Stress Relief Formulations: Navratna Oil, Navratna Extra Thanda Oil, Navratna Gold Cool Oil, Navratna Therapy Range, Navratna Cool Talc, and Dermicool Prickly Heat Powder, Soaps, and Sprays.
  • Personal Care & Daily Hydration: BoroPlus Antiseptic Cream, BoroPlus Doodh Kesar Body Lotion, BoroPlus Aloe Vera Gel, BoroPlus Vasocare Petroleum Jelly, BoroPlus Soft Cream, and BoroPlus Lip Balm.
  • Hair & Scalp Care Ecosystem: Kesh King Gold Ayurvedic Medicinal Oil, Kesh King Anti-Hairfall Shampoo & Conditioner, Kesh King Gold Intensive Hair Growth Serum, Emami 7 Oils in One, and Brillare Hair Treatment Shots.
  • Male Grooming & D2C Lifestyle: Smart And Handsome Face Wash, Face Creams, Sunscreens, Body Washes, Sheet Masks, HE Deodorants, and The Man Company’s premium beard grooming, fine fragrances, and D2C skincare regimens.
  • Functional Nutrition & Beverages: AloFrut range of aloe vera-pulp based fruit juices, Mocktails, and energy drinks under Axiom Ayurveda.

In terms of customer concentration under Ind AS 108 disclosures, no single external customer accounted for 10% or more of the company’s total consolidated revenue in FY 2025-26, highlighting an exceptionally diversified retail consumption base. Indigenous raw materials accounted for 91% of domestic sourcing requirements, with 28% procured directly from micro, small, and medium enterprises (MSMEs) and agricultural cultivator clusters.

The Names You Know: Key Brands & Flagship Portfolio

Emami’s brand architecture represents decades of proprietary category creation, strategic acquisitions, and systematic brand extensions across modern lifestyle formats:

Brand / Product Name Category / Business Segment Target Market & Key Positioning
Navratna Cooling Hair Oils & Talcs Therapeutic scalp cooling, stress relief, and headache relaxation; endorsed by Varun Dhawan and Kapil Sharma
BoroPlus Antiseptic & Skincare Platforms Trusted Ayurvedic skin protection, winter dryness healing, soft moisturisation, and aloe vera hydration; endorsed by Akshay Kumar
Zandu Ayurvedic Healthcare & OTC Century-old legacy in therapeutic balms, chronic joint relief (Ortho Vedic), digestive health (Pancharishta), and preventive immunity; endorsed by Sonu Sood
Dermicool Summer Care & Prickly Heat Immediate prickling heat relief, sensory body cooling, and sweat absorption via talc, shower gels, and prickly heat sprays
Kesh King Medicinal Hair & Scalp Care Clinically proven anti-hairfall therapy combining traditional Tel Pak Vidhi with Gro-Biotin actives; endorsed by Shilpa Shetty
Smart And Handsome Men’s Grooming & Personal Care Contemporary male skin health, multi-action brightening, UV defense, and lifestyle grooming; endorsed by Kartik Aaryan
The Man Company Premium D2C Male Grooming Digital-native, urban lifestyle grooming spanning beard oils, toxin-free body care, and bespoke fine fragrances
Brillare Science-Backed Personal Care 100% natural, chemical-free professional salon hair and skin treatments formulated with concentrated botanical actives
Creme 21 International Skincare German skincare heritage delivering deep moisturisation, pro-vitamin B5 nourishment, and gentle body care across global markets
Axiom / AloFrut Health Beverages & Nutrition Functional health juices infused with aloe vera chunks, providing natural hydration and digestive wellness

Mapping the Domestic & Global Reach (India vs. Exports)

Emami’s commercial network spans 70 countries globally. Domestic operations account for the majority of sales, complemented by a resilient international presence managed across four overseas clusters: MENAP (Middle East, North Africa, Pakistan), SAARC & Southeast Asia, CIS & Eastern Europe, and Africa & the Americas.

Geographic Market / Territory Consolidated Revenue (₹ Crores) % Share of Total Revenue Key Territories & Operational Dynamics
India (Domestic Business) 3,099.20 82.00% Pan-India coverage across 5.4 million retail outlets; 3,400+ stockists
International Business (Exports & Overseas) 680.31 18.00% Bangladesh, UAE, Saudi Arabia, Russia, Nepal, Sri Lanka, Egypt, Kenya, Germany
Total Consolidated Revenue 3,779.51 100.00% Global FMCG footprint spanning over 70 export destinations

Within the International Business division, the regional revenue distribution reflects 42% from MENAP, 40% from SAARC and Southeast Asia, 12% from CIS and Eastern Europe, and 6% from Africa, the Americas, and other geographies. Notably, 88% of Emami’s international workforce is hired locally, ensuring deep regional consumer insights, regulatory adherence, and swift route-to-market execution.

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

Emami operates five captive manufacturing units across India and one dedicated international facility in Gazipur, Bangladesh, delivering an aggregate installed production capacity of 1,30,698 MTPA. This physical infrastructure is supported by an asset-light network of over 35 third-party contract manufacturing locations globally:

  • Pacharia, Guwahati, Assam: Established in 2017; total site area of 1,32,709 sq. metres; annual capacity of 64,648 MTPA; certified under ISO 9001, ISO 14001, ISO 45001, and cGMP.
  • Amingaon, Guwahati, Assam: Established in 2003; total site area of 10,336 sq. metres; annual capacity of 17,180 MTPA; fully certified under ISO 9001, ISO 14001, ISO 45001, and cGMP standards.
  • Pantnagar, Uttarakhand: Established in 2008 (via Zandu integration); site area of 18,638 sq. metres; annual capacity of 17,508 MTPA; specialised in Ayurvedic tablet compression and balms.
  • Masat, Dadra and Nagar Haveli: Established in 1974; site area of 18,383 sq. metres; annual capacity of 2,000 MTPA; certified for personal care liquids and creams.
  • Vapi, Gujarat: Established in 1941 (legacy Zandu facility); site area of 12,714 sq. metres; annual capacity of 13,262 MTPA; focuses on classical Ayurvedic healthcare extracts and oils.
  • Gazipur, Bangladesh: Established in 2014; site area of 6,717 sq. metres; annual capacity of 16,100 MTPA; serving the growing personal care demand in Bangladesh.
  • Central R&D Centre (Kolkata): Spanning 24,000 sq. ft., this facility houses 166 scientific personnel, research experts, and technicians across the Consumer Care and Healthcare divisions, maintaining NABL accreditation, DSIR recognition, and WHO-GMP compliance.
  • Offices & Logistics Infrastructure: Corporate headquarters at Emami Tower (Kolkata), four regional administrative offices (New Delhi, Mumbai, Hyderabad, Kolkata), and 26 regional distribution depots covering 24 Indian states.

📊 The Financial Health: Emami Financial Statements & Numbers Simplified

Multi-Year Financial Highlights (₹ in Crores)

The following multi-year performance summary reflects Emami Limited’s financial trajectory across five consecutive fiscal years (FY 2021-22 to FY 2025-26), illustrating structural margin expansion, consistent net profitability, and debt-free balance sheet discipline:

Financial Metric FY 2025-26 FY 2024-25 FY 2023-24 FY 2022-23 FY 2021-22 Latest YoY (%)
Revenue from Operations 3,779.51 3,809.19 3,578.09 3,405.73 3,187.22 -0.78%
Operating EBITDA 963.64 1,025.11 949.54 862.76 952.37 -6.00%
Operating EBITDA Margin (%) 25.50% 26.91% 26.54% 25.33% 29.88% –
Profit Before Tax (PBT) 846.06 893.86 790.83 669.55 688.01 -5.35%
Profit After Tax (Attributable to Owners) 775.26 806.47 723.53 639.57 838.99 -3.87%
Adjusted PAT 873.86 899.02 810.82 789.46 854.41 -2.80%
Adjusted PAT Margin (%) 23.12% 23.60% 22.66% 23.18% 26.81% –
Total Equity / Net Worth 2,923.98 2,694.79 2,446.59 2,302.80 2,076.60 +8.50%
Capital Employed 3,044.82 2,755.44 2,096.36 2,036.13 2,061.74 +10.50%
Total Borrowings 122.38 62.08 65.69 73.61 263.71 +97.13%
Total Assets 3,836.44 3,533.62 3,279.70 3,109.85 3,057.48 +8.57%
Return on Equity (ROE on Adj. PAT) (%) 26.53% 29.80% 33.14% 34.28% 46.28% –
Return on Capital Employed (ROCE) (%) 25.75% 30.30% 32.13% 33.08% 40.54% –
Basic Earnings Per Share (₹) 17.76 18.48 16.58 14.49 18.88 -3.90%
Dividend Per Share (₹) 10.00 10.00 8.00 8.00 8.00 0.00%

Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)

The following statement reflects Emami Limited’s Consolidated Statement of Profit and Loss for the fiscal years ended March 31, 2026 and March 31, 2025, prepared under Ind AS Schedule III:

Particulars FY 2025-26 (₹ Crores) FY 2024-25 (₹ Crores) Latest YoY (%)
Revenue from Operations 3,779.51 3,809.19 -0.78%
Other Income 85.11 68.11 +24.96%
Total Income 3,864.63 3,877.30 -0.33%
Expenses
Cost of Materials Consumed 756.06 724.13 +4.41%
Purchases of Stock-in-Trade 438.41 448.32 -2.21%
(Increase) / Decrease in Inventories of Finished Goods, Stock-in-Trade and WIP (56.46) 21.78 N/M
Employee Benefits Expense 479.09 447.02 +7.17%
Other Expenses 1,198.77 1,142.83 +4.89%
Total Expenses (Before Finance Costs, D&A, Exceptional Items and Tax) 2,815.88 2,784.08 +1.14%
Operating EBITDA (excluding Other Income) 963.64 1,025.11 -6.00%
Operating Profit (EBIT) 772.08 834.42 -7.47%
Finance Costs 11.13 9.34 +19.16%
Depreciation and Amortisation Expense 177.34 178.21 -0.49%
Share of Loss of Associates (Net) (4.07) (11.81) -65.54%
Profit Before Exceptional Items and Tax 856.21 893.86 -4.21%
Exceptional Items (10.15) 0.00 N/M
Profit Before Tax (PBT) 846.06 893.86 -5.35%
Tax Expense
Current Tax (Including MAT) 172.96 178.72 -3.22%
MAT Credit Entitlement (84.16) (83.91) +0.30%
Deferred Tax Credit (17.99) (3.69) +387.53%
Total Tax Expense 70.81 91.12 -22.29%
Profit for the Year (PAT) 775.26 802.74 -3.42%
Profit Attributable to Equity Holders of the Parent 775.26 806.47 -3.87%
Profit Attributable to Non-Controlling Interests (0.01) (3.72) -99.73%

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

The consolidated assets and liabilities architecture of Emami Limited as of March 31, 2026 and March 31, 2025 is detailed below:

Balance Sheet Line Item As at March 31, 2026 (₹ Crores) As at March 31, 2025 (₹ Crores) Latest YoY (%)
Non-Current Assets
Property, Plant and Equipment 529.24 544.55 -2.81%
Capital Work-in-Progress (CWIP) 0.79 13.28 -94.05%
Investment Properties 40.07 51.08 -21.55%
Goodwill on Consolidation 68.19 68.19 0.00%
Other Intangible Assets 206.81 292.22 -29.23%
Right of Use Assets 42.15 28.34 +48.73%
Intangible Assets Under Development 0.58 1.69 -65.68%
Investments Accounted for Using Equity Method 86.59 111.89 -22.61%
Financial Assets: Non-Current Investments 275.85 139.83 +97.28%
Financial Assets: Non-Current Loans 4.75 5.25 -9.52%
Financial Assets: Other Non-Current Financial Assets 11.40 10.20 +11.76%
Deferred Tax Assets (Net) 626.17 523.93 +19.51%
Other Non-Current Assets 8.99 9.53 -5.67%
Total Non-Current Assets 1,901.58 1,799.96 +5.65%
Current Assets
Inventories 399.57 308.10 +29.69%
Financial Assets: Current Investments 471.88 424.02 +11.29%
Financial Assets: Trade Receivables 343.32 451.29 -23.92%
Financial Assets: Cash and Cash Equivalents 176.75 104.63 +68.93%
Financial Assets: Bank Balances Other than Cash & Cash Equivalents 233.09 168.28 +38.51%
Financial Assets: Current Loans 23.19 4.20 +452.14%
Financial Assets: Other Current Financial Assets 72.88 129.54 -43.74%
Current Tax Assets (Net) 0.72 0.45 +60.00%
Other Current Assets 213.46 143.15 +49.12%
Total Current Assets 1,934.86 1,733.66 +11.61%
TOTAL ASSETS 3,836.44 3,533.62 +8.57%
Equity
Equity Share Capital 43.65 43.65 0.00%
Other Equity 2,880.33 2,651.14 +8.64%
Total Equity Attributable to Equity Holders of Parent 2,923.98 2,694.79 +8.50%
Non-Controlling Interests (1.54) (1.43) +7.69%
Total Equity 2,922.43 2,693.36 +8.50%
Non-Current Liabilities
Non-Current Borrowings 0.00 0.00 N/M
Non-Current Lease Liabilities 24.12 17.28 +39.58%
Other Non-Current Financial Liabilities 3.21 3.04 +5.59%
Non-Current Provisions 31.35 19.29 +62.52%
Deferred Tax Liabilities (Net) 5.93 8.41 -29.49%
Other Non-Current Liabilities 11.15 12.89 -13.50%
Total Non-Current Liabilities 75.76 60.92 +24.36%
Current Liabilities
Current Borrowings 122.38 62.08 +97.13%
Current Lease Liabilities 15.42 10.42 +47.98%
Trade Payables: Micro and Small Enterprises 53.00 56.07 -5.48%
Trade Payables: Other than Micro and Small Enterprises 424.07 379.53 +11.74%
Total Trade Payables 477.07 435.60 +9.52%
Other Current Financial Liabilities 66.63 125.79 -47.03%
Other Current Liabilities 38.47 42.29 -9.03%
Current Provisions 99.04 85.32 +16.08%
Current Tax Liabilities (Net) 19.24 17.83 +7.91%
Total Current Liabilities 838.25 779.35 +7.56%
Total Liabilities 914.01 840.27 +8.78%
TOTAL EQUITY AND LIABILITIES 3,836.44 3,533.62 +8.57%

Working Capital Cycle & Schedule III Statutory Ratio Explanations

Working capital management during FY 2025-26 demonstrated operational discipline amidst supply chain recalibrations prompted by the GST transition and commodity cost hedging. Overall net working capital shortened to 56 days compared to 58 days in the prior financial year.

Key Working Capital Metric / Ratio FY 2025-26 FY 2024-25 Variance (%) Management Statutory Explanation for Variance
Trade Receivables (Days) 33 Days 43 Days -23.26% Enhanced collection efficiency and structured credit terms across organised retail
Inventory (Days) 39 Days 30 Days +30.00% Strategic buffer inventory procured to counter input cost inflation in crude/botanicals
Trade Payables (Days) 46 Days 42 Days +9.52% Negotiated procurement terms and expanded supplier payment schedules
Other Receivables (Days) 30 Days 27 Days +11.11% Temporary timing lags in statutory GST input tax credit reconciliations
Net Working Capital (Days) 56 Days 58 Days -3.45% Consistent cash-to-cash conversion cycle across domestic retail touchpoints
Debt-to-Equity Ratio (times) 0.04x 0.02x +100.00% Variance is primarily due to short-term working capital borrowings availed during the year
Debt Service Coverage Ratio (DSCR) (times) 6.96x 13.48x -48.37% Variance driven by higher short-term working capital borrowing repayments scheduled in FY26
Return on Investment (ROI) (%) 4.60% 8.65% -46.82% Variance on account of lower treasury yields and reduced mark-to-market income on current investments
Current Ratio (times) 2.13x 2.04x +4.41% Healthy liquidity cushion with liquid current assets comfortably exceeding current liabilities
Interest Coverage Ratio (times) 77.93x 96.73x -19.44% Comfortable coverage levels despite marginal uptick in finance costs from lease liabilities

Cash Flow: Tracking the Money Movement

Emami’s Consolidated Statement of Cash Flows underscores strong underlying cash generation from operating activities, enabling self-funded capital expenditures, value-accretive brand acquisitions, and sustained shareholder returns:

Cash Flow Summary Statement FY 2025-26 (₹ Crores) FY 2024-25 (₹ Crores) Latest YoY (%)
Profit Before Tax (PBT) 846.06 893.86 -5.35%
Total Operating Non-Cash & Working Capital Adjustments 126.37 186.80 -32.35%
Cash Generated from Operations 972.44 1,080.66 -10.01%
Less: Direct Taxes Paid (Net of Refund) 171.90 184.80 -6.98%
Net Cash Flows Generated from Operating Activities 800.53 895.86 -10.64%
Purchase of Property, Plant & Equipment and Intangibles (CapEx) 43.32 44.57 -2.80%
Proceeds from Sale of Property, Plant & Equipment 25.75% 30.30% –
Net Movement in Current & Non-Current Investments & Deposits (150.75) (296.71) -49.19%
Net Cash Flows Used in Investing Activities (181.14) (340.14) -46.75%
Net Proceeds / (Repayment) of Short-Term Borrowings 25.75% 30.30% –
Consideration Paid for Non-Controlling Interests of Subsidiary (59.21) (119.95) -50.64%
Interest and Lease Liabilities Paid (31.62) (24.27) +30.28%
Dividends Paid to Shareholders (523.80) (349.20) +50.00%
Net Cash Flows Used in Financing Activities (554.48) (499.61) +10.98%
Effect of Foreign Exchange Fluctuation 7.22 (4.44) N/M
Net Increase / (Decrease) in Cash & Cash Equivalents 72.13 51.67 +39.60%
Cash & Cash Equivalents at Beginning of the Year 104.63 52.95 +97.60%
Cash & Cash Equivalents at End of the Year 176.75 104.63 +68.93%

Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange

Capital deployment during FY 2025-26 maintained an asset-light, high-return discipline, balancing manufacturing modernisation with intensive scientific claim substantiation and global market registration:

  • Capital Expenditure & CWIP: Consolidated capital expenditure incurred during the year stood at ₹43.32 Crores (compared to ₹44.57 Crores in FY 2024-25). Capital Work-in-Progress (CWIP) declined sharply from ₹13.28 Crores to ₹0.79 Crores following the operationalisation of automated filling lines in Amingaon and Pacharia. Intangible assets under development moderated to ₹0.58 Crores.
  • Research & Development Expenditure: Total standalone R&D investment amounted to ₹30.75 Crores, representing 0.80% of total company turnover. This comprised capital R&D expenditure of ₹1.17 Crores and recurring scientific operational expenditure of ₹29.58 Crores, financing 11 clinical efficacy studies, DNA fingerprinting of botanicals, and formulation overhauls.
  • Foreign Exchange Earnings & Outgo (Standalone Section 134(3)(m)):
    • Total Foreign Exchange Earned: ₹189.80 Crores (comprising export sales of ₹146.17 Crores, dividends of ₹33.88 Crores, royalties of ₹8.33 Crores, and guarantee commission/interest of ₹1.42 Crores). Standalone export turnover reached ₹162.72 Crores.
    • Total Foreign Exchange Used: ₹50.49 Crores (comprising raw materials import of ₹43.97 Crores, capital goods of ₹0.32 Crores, and professional/other expenses of ₹6.20 Crores).
    • Net Foreign Exchange Surplus: ₹139.31 Crores, affirming the company’s net foreign exchange earning profile.

👥 Power & Control: Emami Governance, Leadership & Shareholding Pattern

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

Emami’s governance structure comprises a 16-member Board of Directors, balanced equally between executive/promoter members and independent non-executive professionals with deep expertise in finance, corporate governance, banking, and marketing:

Name of Director / KMP Designation / Role DIN Category
Shri Radhe Shyam Agarwal Chairman Emeritus & Non-Executive Director 00152996 Promoter, Non-Executive
Shri Radhe Shyam Goenka Chairman & Non-Executive Director 00152880 Promoter, Non-Executive
Shri Harsha Vardhan Agarwal Vice-Chairman & Managing Director 00150089 Promoter, Executive
Shri Mohan Goenka Vice-Chairman & Whole Time Director 00150034 Promoter, Executive
Shri Sushil Kumar Goenka Whole Time Director 00149916 Promoter, Executive
Smt. Priti A. Sureka Whole Time Director 00319256 Promoter, Executive
Shri Prashant Goenka Whole Time Director 00703389 Promoter, Executive
Shri Aditya Vardhan Agarwal Non-Executive Director 00149717 Promoter, Non-Executive
Shri Anand Nandkishore Rathi Independent Director (Chairman, Audit Committee) 00112853 Independent, Non-Executive
Shri Chandra Kumar Dhanuka Independent Director (Chairman, SRC) 00005684 Independent, Non-Executive
Shri Debabrata Sarkar Independent Director 02502618 Independent, Non-Executive
Dr. (Advocate) Mamta Binani Independent Director 00462925 Independent, Non-Executive
Shri Anjani Kumar Agrawal Independent Director 08579812 Independent, Non-Executive
Shri Anjan Snehmoy Chatterjee Independent Director 00200443 Independent, Non-Executive
Smt. Avani Vishal Davda Independent Director 07504739 Independent, Non-Executive
Shri Rajiv Khaitan Lead Independent Director 00071487 Independent, Non-Executive
Shri N. H. Bhansali CEO – Finance, Strategy & Business Development and CFO – Key Managerial Personnel
Shri Ravi Varma Company Secretary & Compliance Officer FCS 9531 Key Managerial Personnel

Who Owns the Stock? Shareholding Pattern

The shareholding structure of Emami Limited as of March 31, 2026 reflects stable promoter ownership, substantial institutional participation from domestic and foreign asset managers, and minimal retail fragmentation:

Category of Shareholder Number of Shares Held % of Total Issued Shares
Promoter & Promoter Group 23,93,93,412 54.84%
Indian Promoters (Individuals / HUFs) 2,92,97,314 6.71%
Indian Promoter Corporate Bodies (Suraj Finvest, Diwakar Finvest, etc.) 20,84,85,272 47.76%
Foreign Promoters (Individuals / HUFs) 16,10,826 0.37%
Institutional Investors 15,49,51,120 35.49%
Mutual Funds & Alternate Investment Funds (AIFs) 10,86,37,240 24.88%
Foreign Portfolio / Institutional Investors (FPIs / FIIs) 3,74,34,775 8.57%
Banks, Financial Institutions and Insurance Companies 88,65,725 2.03%
Other Institutional Holdings 13,380 0.01%
Public & Non-Institutional Shareholders 4,21,55,468 9.67%
Resident Individuals (including Trusts) 2,45,45,671 5.62%
Private Corporate Bodies & NBFCs 1,40,51,289 3.21%
Non-Resident Indians (NRIs) & Foreign Nationals 19,43,202 0.44%
IEPF and Others 16,15,306 0.40%
Total Issued & Paid-Up Capital 43,65,00,000 100.00%

Two major promoter corporate entities hold substantial equity blocks: Suraj Finvest Private Limited holding 10,56,30,326 shares (24.20%) and Diwakar Finvest Private Limited holding 9,87,94,786 shares (22.63%). Among individual promoters, Smt. Priti A. Sureka holds 1,65,04,702 shares (3.78%), Shri Rajkumar Goenka holds 11,95,247 shares (0.27%), and Shri Harsha Vardhan Agarwal holds 2,29,074 shares (0.05%).

🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities

Subsidiaries, Associates, & Joint Ventures

Emami Limited manages its international distribution and fast-growing domestic D2C portfolios through eleven non-material subsidiaries and four associate entities:

Entity Name Relationship Jurisdiction / Country % Equity Holding Turnover (₹ Crores) PAT / (Loss) (₹ Crores)
Emami Bangladesh Limited Wholly-Owned Subsidiary Bangladesh 100.00% Operational Profitable
Emami International FZE Wholly-Owned Subsidiary Dubai, UAE 100.00% Operational Profitable
Creme 21 GmbH Step-down Subsidiary Germany 100.00% Operational Profitable
Overseas International FZE Step-down Subsidiary Dubai, UAE 100.00% Operational Profitable
Pharma Derm S.A.E. Co. Step-down Subsidiary Egypt 90.60% Operational Profitable
Emami International Personal Care LLC Step-down Subsidiary Dubai, UAE 100.00% Operational Profitable
Emami Neo-Herbals International Ltd Step-down Subsidiary UAE 99.99% Operational Profitable
Emami Rus (LLC) Step-down Subsidiary Russia 99.99% Operational Profitable
Emami Lanka (Pvt.) Ltd Wholly-Owned Subsidiary Sri Lanka 100.00% Operational Profitable
Brillare Science Limited Wholly-Owned Subsidiary India 100.00% Operational Profitable
Helios Lifestyle Limited (The Man Company) Wholly-Owned Subsidiary India 100.00% Operational Profitable
Axiom Foods & Beverages Pvt. Ltd Associate Entity India 26.00% 190.71 21.46
Axiom Packwell Pvt. Ltd Associate Entity India 26.00% 7.36 (0.11)
Axiom Ayurveda Private Limited Associate Entity (Subsidiary post-FY26) India Strategic Stake Operational Gain: ₹2.82
Cannis Lupus Services India Pvt. Ltd Associate Entity India Strategic Stake Operational Loss: ₹(2.30)
TruNative F & B Pvt. Ltd Associate Entity India Strategic Stake Operational Loss: ₹(2.18)

Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities

Emami’s conservative capital allocation maintains robust liquidity reserves across top-tier credit instruments while fulfilling operational and legal commitments:

  • Treasury & Strategic Investments: Current liquid investments in debt mutual funds, commercial papers, and AIFs stood at ₹471.88 Crores as of March 31, 2026. Non-current quoted investments included 79,46,000 equity shares of Emami Paper Mills Limited valued at ₹44.97 Crores (designated at FVTOCI) and quoted Non-Convertible Debentures of ₹60.35 Crores.
  • Banking Consortium: Operating facilities and cash credit limits are syndicated across leading financial institutions including ICICI Bank Ltd., HDFC Bank Ltd., HSBC Ltd., DBS Bank Ltd., Citi Bank N.A., IndusInd Bank Ltd., and Standard Chartered Bank.
  • Credit Ratings: CARE Ratings reaffirmed CARE AA+; Stable for long-term bank facilities and CARE A1+ for short-term facilities. India Ratings & Research reaffirmed IND AA+/Stable and IND A1+, validating strong creditworthiness and cash flow visibility.
  • Capital Commitments: Estimated contractual capital commitments net of advances stood at ₹60.02 Crores (including ₹56.98 Crores committed to Alternative Investment Funds). Export Promotion Capital Goods (EPCG) export obligations to be fulfilled totaled ₹1.15 Crores.
  • Contingent Liabilities: The company discloses contingent liabilities in respect of pending litigations and tax disputes (Notes 3.43 and 3.46), with the management and legal advisors assessing no probable material economic outflow that could undermine financial stability.

🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs

Competitive Advantages & Economic Moats

Emami’s business model is defended by five durable economic moats that preserve pricing power and operating profitability across economic cycles:

  • Category Monopoly in Niche Platforms: Unlike commoditised soaps or detergents, Emami dominates high-gross-margin sub-segments. Navratna controls the cooling oil space, BoroPlus commands antiseptic cream usage, Zandu Balm and Mentho Plus lead topical headache balms, and Dermicool anchors summer relief talcs.
  • Omnichannel Last-Mile Reach: Products are retailed across 5.4 million stores, supported by 3,400+ direct distributors and automated DMS/SFA platforms. Project Phoenix has further institutionalised urban outlet throughput while rural vans and sub-stockist models ensure deep village penetration.
  • Heritage Ayurvedic R&D with Modern Clinical Proof: The company’s 24,000 sq. ft. Kolkata R&D centre validates traditional Ayurvedic wisdom with contemporary bio-assays, DNA fingerprinting, and clinical trials, preventing disruption from non-credentialed D2C entrants.
  • Asset-Light Manufacturing Flexibility: Operating a hybrid configuration of 6 captive plants and 35+ contract sites allows Emami to optimize geographic freight costs, scale peak seasonal volumes rapidly, and keep capital expenditure constrained to ~1.1% of sales.
  • Debt-Free Balance Sheet with Disciplined M&A: A net debt-free capital structure provides strategic headroom to acquire and integrate founder-led consumer platforms (Zandu, Kesh King, Dermicool, The Man Company, AloFrut) without diluting shareholder equity.

What Could Go Wrong? Key Challenges & Business Risks

While fundamentally stable, Emami’s business operations remain exposed to specific strategic and macro-environmental risks:

  • Seasonality & Climate Volatility: Summer categories (cooling oils, Dermicool) and winter products (BoroPlus, petroleum jelly) remain sensitive to erratic weather. A mild winter or early, rain-interrupted summer suppresses volume off-take.
  • Input Commodity Price Volatility: Key raw materials—including menthol, light liquid paraffin, edible herbs, and polymers—are tied to agricultural yield cycles and crude oil derivatives. Geopolitical instability in the Middle East poses supply-chain and freight cost risks.
  • Down-Trading & D2C Competition in Urban Niches: Inflationary pressures can trigger consumer down-trading toward smaller Low Unit Packs (LUPs), while venture-funded D2C brands aggressively contest the premium skincare and haircare space.
  • Geopolitical & Currency Turbulence in Overseas Markets: With MENAP representing 42% of international revenues, regional conflicts, import curbs, or currency devaluations in Africa and South Asia can compress export earnings.

The Next Chapter: Growth, Order Pipeline & CapEx Initiatives

Emami’s forward strategy centres on the “Now Next” transformation framework, designed to expand its total addressable market while modernising the core:

  • Scaling the Non-Seasonal & Mainstream Mix: Growing non-seasonal products beyond the current 56% domestic revenue share through all-year extensions of BoroPlus (soft creams, aloe vera gels) and Dermicool (soaps, shower gels, prickly heat sprays).
  • New-Age Growth Engines (25% Revenue Ambition by FY30): The company’s strategic startup investments (The Man Company, Brillare, Axiom Ayurveda, IncNut Digital) currently contribute 6% of consolidated sales. Emami aims to scale this vertical seven-fold to reach ~25% of consolidated revenues by FY30 via digital cross-selling, retail distribution expansion, and supply chain synergies.
  • Omnichannel Route-to-Market Acceleration: Deepening quick commerce penetration, which expanded 2.2x in FY26 to represent 20% of domestic e-commerce. Expanding chemist channel penetration for the Zandu healthcare portfolio and advancing digital teleconsultations via ZanduCare.
  • Enterprise-Wide AI Integration: Rolling out an AI-native secondary sales platform featuring automated stock-out alerts, smart order recommendations, and predictive inventory deployment across 26 logistics depots.

The Verdict: Strategic Outlook & Conclusion

Emami Limited enters FY 2026-27 with fortified structural foundations. While FY 2025-26 tested operational agility through external climate aberrations and GST recalibration, the company demonstrated the resilience of its gross margins (expanding 130 bps to 69.90%) and preserved operating EBITDA at ₹963.64 Crores.

Supported by a debt-free balance sheet, ₹2,923.98 Crores in net worth, and a proven ability to seed, acquire, and scale consumer franchises, Emami is positioned to benefit from reviving rural consumption while riding the premiumisation wave across urban digital platforms.

Frequently Asked Questions (FAQs) About Emami

Q1: What does Emami Limited manufacture and what are its flagship brands?

Emami Limited manufactures and markets a diverse portfolio of Ayurvedic, healthcare, and personal care products. Its flagship consumer brands include Navratna (cooling hair oils and talcs), BoroPlus (antiseptic and moisturizing skincare), Zandu (pain balms, healthcare generics, and digestive tonics), Dermicool (prickly heat powders and summer body wash), Kesh King (Ayurvedic medicinal anti-hairfall oil and shampoo), Smart And Handsome (men’s personal grooming), and The Man Company (premium D2C male lifestyle grooming).

Q2: What were Emami’s revenue and net profit in FY 2025-26?

In the fiscal year ended March 31, 2026, Emami Limited reported Consolidated Revenue from Operations of ₹3,779.51 Crores (compared to ₹3,809.19 Crores in FY 2024-25). Consolidated Operating EBITDA stood at ₹963.64 Crores, and Consolidated Profit After Tax (PAT) attributable to owners was ₹775.26 Crores.

Q3: Who are the founders and the current Managing Director of Emami?

Emami was founded in 1974 by Shri Radhe Shyam Agarwal and Shri Radhe Shyam Goenka. The enterprise is currently led by Shri Harsha Vardhan Agarwal as Vice-Chairman & Managing Director and Shri Mohan Goenka as Vice-Chairman & Whole Time Director, under the chairmanship of Shri R. S. Goenka and Chairman Emeritus Shri R. S. Agarwal.

Q4: Where are Emami’s manufacturing plants located and what is its export footprint?

Emami operates six captive manufacturing plants: five in India located at Pacharia (Assam), Amingaon (Assam), Pantnagar (Uttarakhand), Masat (Dadra and Nagar Haveli), and Vapi (Gujarat), and one overseas facility in Gazipur (Bangladesh), delivering an aggregate capacity of 1,30,698 MTPA. Products are retailed across more than 70 international countries, with international operations contributing 18% of total consolidated turnover.

Q5: What is Emami’s debt profile, credit rating, and dividend track record?

Emami maintains an essentially debt-free balance sheet with total borrowings of ₹122.38 Crores (comprising short-term working capital facilities) against liquid investments and cash reserves exceeding ₹648 Crores. The company holds top-tier credit ratings of CARE AA+; Stable / CARE A1+ from CARE Ratings and IND AA+/Stable / IND A1+ from India Ratings. In FY 2025-26, Emami declared total dividends of ₹10.00 per share (1,000% on a face value of ₹1), maintaining an uninterrupted dividend payout ratio exceeding 50% of net profits.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.emamiltd.in